Resultados de la búsqueda 11-20 of 3219 for pharmacogenetics

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Probiotics Preventing Immune Checkpoint Inhibitor-Induced Colitis · To evaluate the safety of multi-strain probiotic blend in cancer patients receiving ICIs. · To ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to determine if the drug combination of acalabrutinib, durvalumab, and venetoclax will work to treat Richter's transformation, ...

  3. Patient Blood Management Program

    Our Patient Blood Management Program seeks to improve the blood health of patients receiving care at Mayo Clinic. This includes the use of evidence-based and ...

  4. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS) in addition to the Breast Cancer Risk Assessment ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...

  6. Untitled

    Page 1.

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this research trail is to study the genetic alteration/mutation and immune profiling in surgical resected Non-small Cell Lung Cancer (NSCLC) ...

  8. Enfermedades infecciosas - Ensayos clínicos - Mayo Clinic

    The purposes of this study are to determine if patients treated with fluoroquinolone (FQ) antibiotics have depletion of mitochondrial DNA (mtDNA) in buccal ...

  9. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS) in addition to the Breast Cancer Risk Assessment ...

  10. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS) in addition to the Breast Cancer Risk Assessment ...